Alta Partners
Alta Partners, established in 1996, is a venture capital firm headquartered in Jackson, Wyoming, with additional offices in Denver and Tiburon. The firm specializes in investing in the life sciences and healthcare sectors, focusing on companies that operate in life science, healthcare solutions, and service sectors. Alta Partners is known for its diverse and experienced team, which delivers tangible results for both the companies they invest in and their investors. The firm has evolved its investment strategy over time, currently focusing on stage-agnostic life sciences investments.
Top Sectors
Top Regions
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in Nebraska
aTyr Pharma
Series E in 2015
aTyr Pharma is a biotherapeutics company focused on discovering and developing protein biologics for human therapeutics. Its primary program, ATYR1923, is a clinical-stage product candidate designed to modulate immune engagement in interstitial lung diseases.
aTyr Pharma
Series D in 2013
aTyr Pharma is a biotherapeutics company focused on discovering and developing protein biologics for human therapeutics. Its primary program, ATYR1923, is a clinical-stage product candidate designed to modulate immune engagement in interstitial lung diseases.
aTyr Pharma
Series C in 2010
aTyr Pharma is a biotherapeutics company focused on discovering and developing protein biologics for human therapeutics. Its primary program, ATYR1923, is a clinical-stage product candidate designed to modulate immune engagement in interstitial lung diseases.
aTyr Pharma
Series C in 2009
aTyr Pharma is a biotherapeutics company focused on discovering and developing protein biologics for human therapeutics. Its primary program, ATYR1923, is a clinical-stage product candidate designed to modulate immune engagement in interstitial lung diseases.
aTyr Pharma
Series B in 2007
aTyr Pharma is a biotherapeutics company focused on discovering and developing protein biologics for human therapeutics. Its primary program, ATYR1923, is a clinical-stage product candidate designed to modulate immune engagement in interstitial lung diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.